HAS opinions and decisions
La fiche de bon usage du médicament intitulée « Xolair (omalizumab) dans le traitement de l’asthme sévère», ci-jointe, est adoptée.
See also
HAS opinions and decisions
17/11/2017
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
bpYzNBH9HrYR8Tse